Multiagent PET for risk characterization in sarcoma

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 541-546

  Eary, Janet F ^a,b   Link, Jeanne M ^a   Muzi, Mark ^a   Conrad, Ernest U ^b   Mankoff, David A ^b   White, Jedediah K ^b   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

11C thymidine; 11C verapamil; FMIS.O.; PE.T.; Sarcoma

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBON DIOXIDE C 11; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; RADIOPHARMACEUTICAL AGENT; THYMIDINE C 11; UNCLASSIFIED DRUG; VERAPAMIL C 11; WATER O 15;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; HYPOXEMIA; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SOFT TISSUE SARCOMA; THERAPY RESISTANCE; TREATMENT OUTCOME; UPREGULATION;

CARBON DIOXIDE; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; ISOTOPE LABELING; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SARCOMA; THYMIDINE; VERAPAMIL;

EID: 79954623284     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083717     Document Type: Article

References (14)

1. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814. (Pubitemid 39663314)
2. Krohn KA, O'Sullivan F, Crowley J, et al. Challenges in clinical studies with multiple imaging probes. Nucl Med Biol. 2007;34:879-885. (Pubitemid 47503826)
3. Wells JM, Mankoff DA, Eary JF, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Preliminary patient results. Mol Imaging. 2002;1:145-150.
4. Eary JF, Mankoff DA, Spence AM, et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615-621. (Pubitemid 29076059)
5. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant. J Nucl Med. 1998;39:440-448. (Pubitemid 28136841)
6. Link JM, Bray KE, Krohn KA. Micro-synthesis of 2-(11C)-thymidine to improve yield [abstract]. J Labelled Comp Radiopharm. 2007;50(suppl 1):S207.
7. Elsinga PH, Franssen EJF, Hendrikse NH, et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med.1996;37:1571-1575. (Pubitemid 26321650)
8. Lim J-L, Berridge MS. An efficient radiosynthesis of [F-18] fluoromisonidazole. Appl Radiat Isot. 1993;44:1085-1091.
9. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11- thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290-296. (Pubitemid 26150906)
10. Wells JM, Mankoff DA, Muzi M, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: Compartmental model investigation and mathematical analysis. Mol Imaging. 2002;1:151-159.
11. Alpert NM, Eriksson L, Chang JY, et al. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab. 1984;4:28-34. (Pubitemid 14169316)
12. Muzi M, Mankoff DA, Link JM, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: Studies of healthy humans. J Nucl Med. 2009;50:1267-1275.
13. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S. (Pubitemid 351948041)
14. 18F] FDG PET imaging in soft tissue sarcomas:correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med. 2003;30:695-704. (Pubitemid 36612952)